大分割立体定向放疗治疗乳腺癌脑转移的前瞻性2期试验
这项前瞻性单臂2期试验纳入173例乳腺癌脑转移患者共436个病灶,采用3至5次、每次8 Gy的大分割立体定向放疗。中位随访15个月,1年局部控制率88.6%,1年颅内远处控制率52.1%,中位总生存29个月,放射性坏死发生率6.2%,未观察到3至4级治疗相关不良事件。
要点
- 1年局部控制率88.6%,各亚型均超过86%。
- 中位总生存29个月,中位中枢神经系统无进展生存12个月。
- 放射性坏死发生率6.2%,无3至4级不良事件。
核心结论
- 在现代全身治疗背景下,3至5次每次8 Gy的大分割立体定向放疗对乳腺癌脑转移可实现高局部控制且放射性坏死率低。
研究设计与样本
- 前瞻性单臂2期试验,单中心,纳入173例乳腺癌患者共436个脑转移灶,均接受3至5次每次8 Gy的大分割立体定向放疗。
主要发现
- 中位随访15个月时,1年局部控制率为88.6%,1年颅内远处控制率为52.1%(95% CI,44.7%-60.8%)。
- 中位总生存为29个月(95% CI,21-35个月),可评估病灶患者的中位中枢神经系统无进展生存为12个月(95% CI,9-16个月)。
- 436个治疗病灶中27个(6.2%)发生放射性坏死,未观察到3至4级放疗相关不良事件。
- 各亚型1年局部控制率均超过86%,颅内远处无转移生存率较低,范围为39.7%至57.9%。
关键数值与推荐
- 放疗剂量方案为3至5次、每次8 Gy。
- 1年局部控制率88.6%,1年颅内远处控制率52.1%(95% CI,44.7%-60.8%)。
- 中位总生存29个月(95% CI,21-35个月),中位中枢神经系统无进展生存12个月(95% CI,9-16个月)。
- 放射性坏死发生率6.2%(27/436),无3至4级不良事件。
- 各亚型1年局部控制率超过86%,颅内远处无转移生存率39.7%至57.9%。
临床怎么用
- 对于1至10个脑转移灶的乳腺癌患者,可考虑采用3至5次每次8 Gy的大分割立体定向放疗,以实现高局部控制并限制放射性坏死。
- 治疗决策时应结合现代全身治疗背景,并关注颅内远处控制率相对较低的风险。
局限性
- 本研究为单中心、单臂2期试验,无对照组。
- 中位随访时间为15个月,尚不足以评估长期疗效与晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although fractionated stereotactic radiation therapy (FSRT) remains understudied for the management of breast cancer brain metastases, this study aimed to investigate its therapeutic efficacy and safety in the context of contemporary systemic therapies. We enrolled patients with 1 to 10 brain lesions. METHODS AND MATERIALS: This was a prospective, single-arm, phase 2 trial involving 173 patients with breast cancer and 436 brain metastases, all treated with FSRT at a dose of 3 to 5 fractions of 8 Gy each. The primary endpoint was the local control rate, and secondary endpoints included the intracranial distant control rate, overall survival, and central nervous system progression-free survival. RESULTS: With a median follow-up of 15 months, the 1-year local control rate was 88.6% and the 1-year intracranial distant control rate was 52.1% (95% CI, 44.7%-60.8%). The median overall survival was 29 months (95% CI, 21-35 months), and the median central nervous system progression-free survival for patients with evaluable lesions was 12 months (95% CI, 9-16 months). Of the treated lesions, 27 out of 436 (6.2%) experienced radiation necrosis; no grade 3 or 4 FSRT-related adverse events were observed. Local control rates exceeded 86% at 1 year across all subtypes, whereas the intracranial distant metastasis-free survival was lower, ranging from 39.7% to 57.9%. CONCLUSIONS: In this single-institution trial, FSRT delivered in 3 to 5 fractions of 8 Gy each for breast cancer brain metastases yielded high local control with low rates of radiation necrosis in the background of modern systemic treatment.
引用
- Meng J, Zhang L, Chen J, et al. A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41453455. doi:10.1016/j.ijrobp.2025.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。